Researchers at Massachusetts Eye and Ear developed a preclinical research proof of concept that shows mRNA-based therapies ...

AAVantgarde Bio (AAVantgarde), a clinical-stage, Italian-based international biotechnology company with two proprietary Adeno-Associated Viral (AAV) vector platforms for large gene delivery, today ...

A novel mRNA therapy delivered inside the eye could be effective at treating a blinding condition, reports a preclinical ...

A new preclinical study by Mass Eye and Ear investigators showed that a novel mRNA-based therapy may be able to prevent blindness and scarring from proliferative vitreoretinopathy (PVR) following a ...

A new preclinical study by Mass Eye and Ear investigators showed that a novel mRNA-based therapy may be able to prevent ...

Proliferative vitreoretinopathy (PVR) is an eye condition that leads to blindness and can currently only be addressed with ...

The global macular degeneration treatment market is poised for significant growth, projected to expand from USD 9.1 billion ...

“Every year, NobleCon showcases emerging growth companies from a variety of industries to a relevant investor audience,” said Dr. Musunuri. “I look forward to sharing an update on our clinical ...

Detailed price information for Adverum Biotechnologies Inc (ADVM-Q) from The Globe and Mail including charting and trades.

A team of UC Davis Health researchers has shown that CD34+ stem cells can be safely administered into retinitis pigmentosa ...

A team of UC Davis Health researchers has shown that CD34+ stem cells can be safely administered into retinitis pigmentosa ...